ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on rare blood vessel disease
Disease control Recruiting nowThis early-phase study tests a new treatment called CC-97540 for people with severe ANCA-associated vasculitis that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy disease-causing cells. The main goal is to …
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1, PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug avacopan put to the test for rare blood vessel disease
Disease control Recruiting nowThis study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who are newly diagnosed or have a relapse will take either avacopan or a placebo. The m…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Could immune cells tame autoimmune diseases?
Disease control Recruiting nowThis study tests a new treatment called NKX019, made from donor immune cells engineered to target and calm overactive immune cells. It is for people with certain autoimmune diseases like systemic sclerosis, inflammatory myopathies, or vasculitis. The goal is to see if it is safe …
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated May 05, 2026 11:54 UTC